| Literature DB >> 35069041 |
Jinping Li1, Sheng Zhao1, Zaisheng Ling1, Daqing Li1, Guangsheng Jia1, Chenglei Zhao1, Xue Lin1, Yanmei Dai1, Huijie Jiang1, Song Wang2.
Abstract
Background: This study aims to evaluate the application of dual-energy computed tomography (DECT) for multiparameter quantitative measurement in early-stage hepatocellular carcinoma (HCC).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35069041 PMCID: PMC8752295 DOI: 10.1155/2022/2146343
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161
Characteristics of patients.
| Male ( | Female ( |
| |
|---|---|---|---|
| Agea | 53(46,60) | 58(57,62) | 0.060 |
| Etiologyb | |||
| HBV | 11 (52.38%) | 5 (55.56%) | 1.000 |
| Others | 10 (47.62%) | 4 (44.44%) | |
| AFP (ng/mL)b | |||
| ≤9 | 12 (57.14%) | 2 (22.22%) | 0.118 |
| >9 | 9 (42.86%) | 7 (77.78%) | |
| CEA (ng/mL)b | |||
| ≤5 | 11 (52.38%) | 4 (44.44%) | 1.000 |
| >5 | 10 (47.62%) | 5 (55.56%) | |
| BMI (kg/m2)b | |||
| <18.5 | 3 (14.29%) | 3 (33.33%) | 0.345 |
| 18.5–24.9 | 10 (47.62%) | 2 (22.22%) | |
| >25 | 8 (38.10%) | 4 (44.44%) | |
aMedian (IQR); bn(%).
CT values of early-stage hepatocellular carcinoma on different energy levels.
| Scan phase (keV) | AP | PVP |
|
|
|---|---|---|---|---|
| 40 | 232.55 ± 45.74 | 190.42 ± 80.18 | 2.001 | 0.055 |
| 70 | 102.00 ± 17.42 | 82.79 ± 22.18 | 2.998 | 0.005 |
| 100 | 66.25 ± 10.21 | 56.68 ± 15.45 | 2.269 | 0.030 |
| 140 | 52.50 ± 9.53 | 47.53 ± 23.97 | 0.843 | 0.407 |
P < 0.05 represents a statistically significant difference.
Figure 1The CT values of hepatocellular carcinoma lesions decreased at different energy levels. (a) The arterial phase image at 70 keV. (b) The arterial phase iodine-based image at 70 keV. (c) Spectral curve of lesion on arterial phase. (d) The portal venous phase image at 70 keV. (e) The portal venous phase iodine-based image at 70 keV. (f) Spectral curve of lesion on portal venous phase.
The slope of the spectral attenuation curves on dual phases at different energy intervals (HU/keV).
| Scan phase | AP | PVP |
|
|
|---|---|---|---|---|
|
| 4.39 ± 1.08 | 3.89 ± 1.61 | 1.141 | 0.262 |
|
| 2.79 ± 0.70 | 2.44 ± 1.00 | 1.278 | 0.209 |
|
| 1.82 ± 0.45 | 1.58 ± 0.64 | 1.316 | 0.197 |
P < 0.05 represents a statistically significant difference.
The IC, WC, NIC, and NWC on dual phases.
| Scan phase ( | AP | ΔPVP − AP | PVP |
|---|---|---|---|
| IC (100 | 21.59 ± 10.43 | 2.34 ± 8.18 | 19.25 ± 2.33 |
| WC (mg/cm3) | 1,029.25 ± 16.43 | −4.15 ± 14.23 | 1,033.41 ± 2.48 |
| NIC | 0.17 ± 0.09 | −0.19 ± 0.05 | 0.36 ± 0.05 |
| NWC | 1.01 ± 0.02 | −0.01 ± 0.02 | 1.02 ± 0.01 |
Figure 2Arterial phase spectral parameter. (a) The relationship between Zeff and IC on arterial phase. (b) The relationship between Zeff and N IC on arterial phase. (c) The relationship between Zeff and WC on arterial phase. (d) The relationship between Zeff and NWC on arterial phase.
Figure 3Portal venous phase spectral parameter. (a) The relationship between Zeff and IC on portal venous phase. (b) The relationship between Zeff and NIC on portal venous phase. (c) The relationship between Zeff and WC on portal venous phase. (d) The relationship between Zeff and NWC on portal venous phase.
Figure 4The pre- and post-RFA iodine-based images on arterial phase and corresponding slope of the spectral attenuation curves. (a) The iodine-based image before RFA. (b) The slope of the spectral attenuation curve before RFA. (c) The iodine-based image after RFA. (d) The slope of the spectral attenuation curve after RFA.